Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages ≥ 12 Years to < 18 Years) With Atopic Dermatitis

NCT05456529 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT05456529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05456529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages ≥ 12 Years to < 18 Years) With Atopic Dermatitis
Lead sponsor
Incyte Corporation
Phase
Phase 3
Overall status
Completed
Start date
September 1, 2022
Completion date
May 17, 2024
Enrollment
103 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis (ad)